Skip to main content

Kathleen M. Murphy, PhD

Board Certifications

Molecular Diagnostics


Molecular Pathology


Molecular Diagnostics, Women's Health


ProPath, a Sonic Healthcare anatomic pathology practice, is privileged to include Kathleen M. Murphy, Ph.D., as a part of its world-class leadership team. Dr. Murphy is ProPath’s vice president of research and development and is board certified in molecular diagnostics. She brings robust and varied professional experience and an extensive list of peer-reviewed publications.

Dr. Murphy graduated with a Bachelor of Science degree in medical technology from George Mason University in Fairfax, Virginia. She completed a medical technology certificate from the University of Virginia Medical Center in Charlottesville. She earned a doctoral degree from the University of Louisville, Department of Microbiology and Immunology, in Kentucky. Supervised by Dr. Richard B. Lock, Ph.D., her dissertation was titled Function of Bcl-2 and Bax in the Regulation of Apoptosis. She completed a fellowship in molecular pathology at The Johns Hopkins University School of Medicine in Baltimore, Maryland.

Dr. Murphy has substantial professional experience, including teaching appointments and a collection of medical and laboratory directorships. She started as a medical technologist in the immunology laboratory at the University of Virginia in Charlottesville. She was a lecturer in the biotechnology graduate program at Johns Hopkins University. She’s held multiple teaching appointments in The Johns Hopkins School of Medicine. She was an instructor in the pathology department before becoming an assistant, then associate, professor in the pathology and oncology departments. Other teaching positions include a course in molecular diagnostics at the University of Texas Southwestern, molecular and immunologic diagnostics at Stevenson University in Baltimore, and cancer biology in the graduate program of biotechnology at Johns Hopkins University. Dr. Murphy has considerable leadership experience. She was the director of the Johns Hopkins University Molecular Diagnostics Lab before joining ProPath in Dallas, Texas, as the chief laboratory officer and director of clinical lab operations. She is currently the vice president of research and development at ProPath.

Dr. Murphy has a considerable collection of published manuscripts, books, and a roster of invited talks. She’s published peer-reviewed articles in a variety of prestigious journals, including the American Journal of Surgical Pathology, International Journal of Gynecology, Modern Pathology, and Human Pathology, among others. She also coauthored a book, Molecular Diagnostics in Dermatology: Practical Applications for Molecular Testing for the Diagnosis and Management of the Dermatology Patient.

Dr. Murphy belongs to multiple professional organizations. These include the Association for Molecular Pathology, American Association for Cancer Research, and the American Society for Clinical Pathology. Dr. Murphy is board certified in molecular diagnostics by the American Board of Clinical Chemistry.



George Mason University (BS)
Fairfax, VA

University of Louisville (PhD)
Louisville, KY


Postgraduate Training

Molecular Pathology Fellowship
The Johns Hopkins University School of Medicine
Baltimore, MD


Professional Memberships

Association for Molecular Pathology
American Association for Cancer Research
American Society for Clinical Pathology


Peer-Reviewed Articles

  1. Murphy KM, Carrick K, Gwin K, Rogers V, Koduru P, Ronnett BM, Castrillon DH. Rare complete hydatidiform mole with p57 expression in villous mesenchyme: case report and review of discordant p57 expression in hydatidiform moles. Int J Gynecol. 2022;41(1):45-50.

  2. Chamseddin BH, Lee EE, Kim J, Zhan X, Yang R, Murphy KM, Lewis C, Hosler GA, Hammer ST, Wang RC. Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma. Oncotarget. 2019;10(57):5958-5969.

  3. Savage J, Adams E, Veras E, Murphy KM, Ronnett BM. Choriocarcinoma in women: analysis of a case series with genotyping. Am J Surg Pathol. 2017;41(12):1593-1606.

  4. Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve, M, Menley M, Oliai B, Murphy KM, Manning L, Gutierez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J. Case report: Immune-mediated complete response in a patient with recurrent advanced Ewing sarcoma (EWS) after vigil immunotherapy. J Pediatr Hematol Oncol. 2017;39(4):e183-e186.

  5. Hill AM, Peters J, Rojas A, Hosler GA, Murphy KM. A novel calreticulin mutation in a patient with myeloproliferative neoplasm. Ann Hematol. 2016;95(11):1905-1907.

  6. Bynum J, Murphy KM, DeScipio C, et al. Invasive complete hydatidiform moles: analysis of a case series with genotyping. Int J Gynecol Pathol. 2016;35(2):134-141.

  7. Banet N, DeScipio C, Murphy KM, et al. Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping. Mod Pathol. 2014;27(2):238-254.

  8. Lewis GH, DeScipio C, Murphy KM, et al. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. Int J Gynecol Pathol. 2013;32(2):199-214.

  9. Petersen SM, Gendelman M, Murphy KM, et al. In utero hematopoietic stem cell transplantation in canines: exploring the gestational age window of opportunity to maximize engraftment. Fetal Diagn Ther. 2013;33(2):116-121.

  10. Murphy KM, Descipio C, Wagenfuehr J, et al. Tetraploid partial hydatidiform mole: a case report and review of the literature. Int J Gynecol Pathol. 2012;31(1):73-79.

  11. Gupta M, Vang R, Yemelyanova AV, Kurman R, Li F, Maambo E, Murphy KM, Descipio C, Thompson C, Ronnett B. Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists. Am J Surg Pathol. 2012;36(12):1747-1760.

  12. Vang R, Gupta M, Wu LS, Yemelyanova AV, Kurman R, Murphy KM, Descipio C, Ronnett B. Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis. Am J Surg Pathol. 2012;36(3):443-453.

  13. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18(12):3462-3469.

  14. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, Sharma R, Schoenberg MP, Netto GJ. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol. 2012;43(10):1590-1595.

  15. Youens KE, Hosler GA, Washington PJ, Jenevein EP, Murphy KM. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn. 2011;13(2):160-166.

  16. Pitino A, Squillaci S, Spairani C, Cosimi MF, Feyles E, Ricci D, Bardari F, Graziano M, Morabito F, Cesarani F, Garruso M, Belletti M, Beierl K, Murphy KM. Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature review. Pathologica. 2011;103(5):271-278.

  17. DeScipio C, Haley L, Beierl K, Pandit AP, Murphy KM, Ronnett BM. Diandric triploid hydatidiform mole with loss of maternal chromosome 11. Am J Surg Pathol. 2011;35(10):1586-1591.

  18. Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Phillips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011;11(1):176.

  19. Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs. 2011;29(5):1057-1065.

  20. Lin MT, Tseng LH, Rich RG, Hafez MJ, Harada S, Murphy KM, Eshleman JR, Gocke CD. Δ-PCR, a simple method to detect translocations and insertion/deletion mutations. J Mol Diagn. 2011;13(1):85-92.

  21. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011;68(4):863-870.

  22. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425-1432.

  23. Li F, Shen Y, Köhler U, Sharkey FH, Menon D, Coulleaux L, Malan V, Rio M, McMullan DJ, Cox H, Fagan KA, Gaunt L, Metcalfe K, Heinrich U, Hislop G, Maye U, Sutcliffe M, Wu BL, Thiel BD, Mulchandani S, Conlin LK, Spinner NB, Murphy KM, Batista DA. Interstitial microduplication of Xp22.31: causative of intellectual disability or benign copy number variant? Eur J Med Genet. 2010;53(2):93-99.

  24. Yap KL, Hafez MJ, Mao TL, Kurman RJ, Murphy KM, Shih IM. Lack of a y-chromosomal complement in the majority of gestational trophoblastic neoplasms. J Oncol. 2010;2010:364508.

  25. Jinawath N, Morsberger L, Norris-Kirby A, Williams L, Yonescu R, Argani P, Griffin C, Murphy KM. Complex rearrangement of chromosomes 1, 7, 21, 22 in Ewing sarcoma. Cancer Genet Cytogenet. 2010;201(1):42-47.

  26. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425-432.

  27. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy KM, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16(1):338-347.

  28. Norris-Kirby A, Hagenkord JM, Kshirsagar MP, Ronnett BM, Murphy KM. Abnormal villous morphology associated with triple trisomy of paternal origin. J Mol Diagn. 2010;12(4):525-529.

  29. Mcconnell TG, Norris-Kirby A, Hagenkord JM, Ronnett BM, Murphy KM. Complete hydatidiform mole with retained maternal chromosomes 6 and 11. Am J Surg Pathol. 2009;33(9):1409-1415.

  30. Jinawath N, Norris-Kirby A, Smith BD, Gocke CD, Batista DA, Griffin CA, Murphy KM. A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn. 2009;11(4):359-363.

  31. Murphy KM, McConnell TG, Hafez MJ, Vang R, Ronnett BM. Molecular genotyping of hydatidiform moles: analytic validation of a multiplex short tandem repeat assay. J Mol Diagn. 2009;11(6):598-605.

  32. McConnell TG, Murphy KM, Hafez M, Vang R, Ronnett BM. Diagnosis and subclassification of hydatidiform moles using p57 immunohistochemistry and molecular genotyping: validation and prospective analysis in routine and consultation practice settings with development of an algorithmic approach. Am J Surg Pathol. 2009;33(6):805-817.

  33. Murphy KM, Chen F, Clark DP. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol. 2008;39(3):420-426.

  34. Liang S-L, Lin M-T, Hafez MJ, Gocke CD, Murphy KM, Sokoll LJ, Eshleman JR. Application of traditional clinical pathology quality control techniques to molecular pathology. J Mol Diagn. 2008;10(2):142-146.

  35. Karanjawala ZE, Illei PB, Ashfaq R, Infante J, Murphy KM, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban R. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32(2):188-196.

  36. Cho E, Schiffer J, Murphy KM, Smith B. Isolated granulocytic sarcoma: case reports of three rare presentations and review. Clin Leuk. 2008;2(4):275-279.

  37. Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagn. 2007;9(2):220-227.

  38. Murphy KM, Cohen JS, Goodrich A, Long PP, Griffin CA. Constitutional duplication of a region of chromosome Yp encoding AMELY, PRKY, and TBL1Y: implications for sex chromosome analysis and bone marrow engraftment analysis. J Mol Diagn. 2007;9(3):408-413.

  39. Patel AS, Murphy KM, Hawkins AL, et al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet Cytogenet. 2007;176(2):107-114.

  40. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr Biol. 2007;17(5):431-437.

  41. Lin MT, Rich RG, Shipley RF, Hafez MJ, Murphy KM, Gocke CD, Eshleman JR. A molecular fraction collecting tool for the ABI 310 automated sequencer. J Mol Diagn. 2007;9(5):598-603.

  42. Petersen S, Gendelman M, Murphy KM, et al. Use of T-cell antibodies for donor dosaging in a canine model of in utero hematopoietic stem cell transplantation. Fetal Diagn Ther. 2007;22(3):175-179.

  43. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KM, Berg KD. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol. 2006;14(1):24-30.

  44. Bian Y, Matsubayashi H, Li CP, Abe T, Canto M, Murphy KM, Goggins M. Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: Heteroduplex analysis of limiting dilution PCRs. Cancer Biol Ther. 2006;5(10):1392-1399.

  45. Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagnostics. 2006;8(3):305-311.

  46. Nayer H, Murphy KM, Hawkins AL, et al. Clonal cytogenetic abnormalities and BCL2 rearrangement in interdigitating dendritic cell sarcoma. Leuk Lymphoma. 2006;47(12):2651-2654.

  47. Batista DAS, Vonderheid EC, Hawkins A, Morsberger L, Long P, Murphy KM, Griffin CA. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sé zary syndrome: search for recurrent chromosome abnormalities. Genes Chromosom Cancer. 2006;45:383-391.

  48. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65(10):988-994.

  49. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res. 2006;66(19):9369-9373.

  50. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A. 2005;102(40):14344-14349.

  51. Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood. 2005;106(2):673-680.

  52. Mamelak AJ, Kowalski J, Murphy KM, et al. Downregulation of NDUFA1 and other oxidative phosphorylation-related genes is a consistent feature of basal cell carcinoma. Exp Dermatol. 2005;14(5):336-348.

  53. Murphy KM, Berg KD, Eshleman JR. Sequencing of genomic DNA by combined amplification and cycle sequencing reaction. Clin Chem. 2005;51(1):35-39.

  54. Batista DAS, Hawkins A, Murphy KM, Griffin CA. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: Deletion on the derivative chromosome 9 may or not be present. Cancer Genet Cytogenet. 2005;163(2):164-167.

  55. Cao D, Hafez M, Berg K, Murphy KM, Epstein JI. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity. Am J Surg Pathol. 2005;29(4):467-473.

  56. Swierczynski SL, Hafez MJ, Philips J, Higman MA, Berg KD, Murphy KM. Bone marrow engraftment analysis after granulocyte transfusion. J Mol Diagn. 2005;7(3):422-426.

  57. Jain SK, Persaud D, Perl TM, Pass MA, Murphy KM, Pisciotta JM, Scholl PF, Casella JF, Sullivan DJ. Nosocomial malaria and saline flush. Emerg Infect Dis. 2005;11(7):1097-1099.

  58. Murphy KM, Berg KD, Geiger T, et al. Capillary electrophoresis artifact due to eosin: implications for the interpretation of molecular diagnostic assays. J Mol Diagn. 2005;7(1):143-148.

  59. Cao D, Hustinx SR, Sui G, Bala P, Sato N, Martin S, Maitra A, Murphy KM, Cameron JL, Yeo CJ, Kern SE, Goggins M, Pandey A, Hruban RH. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther. 2004;3(11):1081-1089.

  60. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single agent CEP 701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103(10):3669-3676.

  61. Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan RH, Borowitz MJ, Berg KD, Murphy KM. FLT3 mutations in myeloid sarcoma. Br J Haematol. 2004;126(6):785-791.

  62. Rogers CD, Couch FJ, Brune K, Martin ST, Philips J, Murphy KM, Petersen G, Yeo CJ, Hruban RH, Goggins M. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet. 2004;41(12):e126-e126.

  63. Blakemore K, Hattenburg C, Stetten G,Berg K, South S, Murphy KM, Jones R, Lockwood C. In utero hematopoietic stem cell transplantation with haploidentical donor adult bone marrow in a canine model. Am J Obstet Gynecol. 2004; 190(4):960-973.

  64. Wang M, Murphy KM, Kulesza P, et al. Molecular diagnosis of metastasizing oligodendroglioma: a case report. J Mol Diagn. 2004;6(1):52-57.

  65. Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat. 2004;23(6):546-551.

  66. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM, Berg KD. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Investig. 2003;83(3):419-428.

  67. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, Yeo CJ, Hruban RH, Kern SE. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res. 2003;63(5):994-999.

  68. Murphy KM, Hafez M, Philips J, Yarnell K, Gutshall K, Berg K. Evaluation of temperature gradient capillary electrophoresis for detection of the Factor V Leiden mutation: coincident identification of a novel polymorphism in Factor V. Mol Diagnosis. 2003;7(1):25-40.

  69. Murphy KM, Geiger T, Hafez MJ, Eshleman JR, Griffin CA, Berg KD. A single nucleotide primer extension assay to detect the APC I1307K gene variant. J Mol Diagn. 2003;5(4):222-226.

  70. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96-102.

  71. Murphy KM, Eshleman JR. Simultaneous sequencing of multiple polymerase chain reaction products and combined polymerase chain reaction with cycle sequencing in single reactions. Am J Pathol. 2002;161(1):27-33.

  72. Sohn TA, Bansal R, Su GH, Murphy KM, Kern SE. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002;23(6):949-957.

  73. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62(13):3789-3793.

  74. Peaston AE, Gardaneh M, Franco A, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB, Marshall GM. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer. 2001;85(10):1564-1571.

  75. Su GH, Bansal R, Murphy KM, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A. 2001;98(6):3254-3257.

  76. Berg KD, Brinster NK, Huhn KM, Goggins MG, Jones RJ, Makary A, Murphy KM, Griffin CA, Rosenblum-Vos LS, Borowitz MJ, Nousari HC, Eshleman JR. Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. N Engl J Med. 2001;345(20):1458-1463.

  77. Murphy KM, Streips UN, Lock RB. Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. J Biol Chem. 2000;275(23):17225-17228.

  78. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 2000;7(1):102-111.

  79. Elliott MJ, Murphy KM, Stribinskiene L, et al. Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide. Cancer Chemother Pharmacol. 1999;44(1):1-11.

  80. Murphy KM, Streips UN, Lock RB. Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene. 1999.


  1. Hosler GA, Murphy KM. Ancillary testing for melanoma: current trends and practical considerations. Hum Pathol. 2023 Oct;140:5-21. Epub 2023 May 11.

  2. Hui, P, Buza N, Murphy KM, Ronnett BM. Hydatidiform moles: genetic basis and precision diagnosis. Annu Rev Pathol. 2017;12:449-485.

  3. Ronnett BM, Descipio C, Murphy KM. Hydatidiform moles: ancillary techniques to refine diagnosis. Int J Gynecol Pathol. 2011;30(2):101-16.

  4. Murphy KM, Ronnett BM. Molecular analysis of hydatidiform moles: utilizing p57 immunohistochemistry and molecular genotyping to refine morphologic diagnosis. Pathol Case Rev. 2010;15(4):126-134.

  5. Murphy KM, Berg KD. Mutation and single nucleotide polymorphism detection using temperature gradient capillary electrophoresis. Expert Rev Mol Diagn. 2003;3:811-8.

  6. Berg KD, Murphy KM. “Floaters” in surgical pathology tissues: genetic identity testing potential and pitfalls. Pathol Case Rev. 2003;8:3103-10.


Book Chapters

  1. Murphy KM. Chimerism analysis following hematopoietic stem cell transplantation. In: Czader M, ed. Hematological Malignancies. Totowa, NJ: Humana Press; 2013:137-149. Methods in Molecular Biology; vol 999.

  2. Lock R, Murphy KM. Immunodetecting members of the Bcl-2 family of proteins. In: Blumenthal R, ed. Chemosensitivity: Volume II. Totowa, NJ: Humana Press; 2005:83-96. Methods in Molecular Medicine; vol 111.


  1. Hosler G, Murphy KMMolecular Diagnostics in Dermatology: Practical Applications of Molecular Testing for the Diagnosis and Management of the Dermatology Patient. Berlin, Germany: Springer; 2014.